The content on this site is intended for healthcare professionals only
Dr Hurvitz speaks with ecancertv at SABCS 2016 about the outcomes of the neoMONARCH trial of abemaciclib, a CDK 4/6 inhibitor, in combination with anastrozole for women with HR positive breast cancer.
The study found that, alone or with anastrozole, abemaciclib induced significantly greater cell cycle arrest, defined by reduced Ki67 expression.
These results were first presented at a press conference session, with video available here.
Dr Hurvitz spoke more on CDK4/6 inhibition at an ecancer symposium in Copenhagen, here.
Supported by a grant from Pfizer Inc.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Overview of the management of HER2-low breast cancer patients
